On August 26, 2021, Palmer, Wylie Solang; Wu, Jeffrey; Zipfel, Sheila; Ozboya, Kerem; Weiss, Dahlia published a patent.Quality Control of 2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindoline-5-carboxylic acid The title of the patent was Preparation of bifunctional degraders of interleukin-1 receptor-associated kinases and therapeutic use thereof. And the patent contained the following:
The present disclosure provides bifunctional compounds I [R1 = (un)substituted C1-10 alkyl, C3-10 cycloalkyl, or 3-12 membered heterocyclyl; L = L1L2L3L4L5, each L1-L5 being independently: (a) (un)substituted C3-12 cycloalkyl, (b) (un)substituted C6-12 aryl, (c) (un)substituted 3-12 membered heterocyclyl, etc.; LHM = a ligase harness moiety] or pharmaceutically acceptable salts as IRAK4 degraders via ubiquitin proteasome pathway, and method for treating diseases modulated by IRAK4. E.g., a multi-step synthesis of II, starting from Me 4,6-dichloropyridine-3-carboxylate and tetrahydropyran-4-amine hydrochloride, was described. IRAK4 degradation of exemplified compounds I were measured in multiple runs using HTRF assay and HiBit assay (data given). Pharmaceutical composition comprising I was disclosed. The experimental process involved the reaction of 2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindoline-5-carboxylic acid(cas: 1216805-11-6).Quality Control of 2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindoline-5-carboxylic acid
The Article related to interleukin1 receptor associated kinase irak4 bifunctional degrader pyrrolopyridazinecarbonitrile preparation, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazines and Quinoxalines (Including Piperazines) and other aspects.Quality Control of 2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindoline-5-carboxylic acid
Referemce:
Piperidine – Wikipedia,
Piperidine | C5H11N – PubChem